Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) shares rose 12.7% during mid-day trading on Monday after Piper Sandler raised their price target on the stock from $6.00 to $7.00. Piper Sandler currently has an overweight rating on the stock. Adaptive Biotechnologies traded as high as $6.56 and last traded at $6.56. Approximately 331,482 shares changed hands during trading, a decline of 76% from the average daily volume of 1,403,812 shares. The stock had previously closed at $5.82.
Several other brokerages also recently weighed in on ADPT. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, October 2nd. JPMorgan Chase & Co. increased their price target on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd.
View Our Latest Stock Analysis on Adaptive Biotechnologies
Institutional Investors Weigh In On Adaptive Biotechnologies
Several hedge funds have recently bought and sold shares of ADPT. The Manufacturers Life Insurance Company lifted its position in shares of Adaptive Biotechnologies by 5.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company's stock valued at $177,000 after buying an additional 2,710 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Adaptive Biotechnologies by 30.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company's stock valued at $87,000 after buying an additional 4,000 shares in the last quarter. JTC Employer Solutions Trustee Ltd purchased a new position in Adaptive Biotechnologies in the 3rd quarter valued at $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in Adaptive Biotechnologies by 29.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company's stock valued at $131,000 after purchasing an additional 5,826 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Adaptive Biotechnologies in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 99.17% of the company's stock.
Adaptive Biotechnologies Stock Up 11.5 %
The business has a fifty day simple moving average of $4.85 and a two-hundred day simple moving average of $4.19.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
See Also
Before you consider Adaptive Biotechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptive Biotechnologies wasn't on the list.
While Adaptive Biotechnologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
